{"name":"Silence Therapeutics","slug":"silence-therapeutics","ticker":"SLN","exchange":"NASDAQ","domain":"silence-therapeutics.com","description":"Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.","hq":"London, UK","founded":0,"employees":"88","ceo":"Craig Tooman","sector":"RNAi Therapeutics / Cardiovascular","stockPrice":7.01,"stockChange":0.03,"stockChangePercent":0.43,"marketCap":"$331M","metrics":{"revenue":839000,"revenueGrowth":197.2,"grossMargin":79.5,"rdSpend":67753000,"netIncome":-88612000,"cash":70078000,"dividendYield":0,"peRatio":-18,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"STP-705 patent cliff ($0.00 at risk)","drug":"STP-705","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Atu027 & gemcitabine in treatment arm 1","genericName":"Atu027 & gemcitabine in treatment arm 1","slug":"atu027-gemcitabine-in-treatment-arm-1","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Atu027 & gemcitabine in treatment arm 1","genericName":"Atu027 & gemcitabine in treatment arm 1","slug":"atu027-gemcitabine-in-treatment-arm-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Silence Therapeutics Announces FDA Clearance of IND for STP-705","summary":"Silence Therapeutics announced that the FDA has cleared the Investigational New Drug (IND) application for STP-705, enabling the company to initiate a Phase 1 clinical trial.","drugName":"STP-705","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Silence Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Silence Therapeutics reported its third-quarter 2023 financial results, with a net loss of $13.4 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNdktjdl9KMVdZTUoydHNSUS10NzBxVVBoWDhIYlhrUllTamRGWkI0SmpPeFJ1UWE0MDhIVXUxZWhyMjUzSTZkNFhVc3A5a254cmVFV1MxTTYtcHk3RGUwV3BzZjBoUlZRY2dZbGVLUWFSZHRRODhwODFBT082bHZmdFB0WDNJRzFDbGdIVng0MlhpUlltZ0IwX1Z1QW5CZEJzbWJNNElLblYtWWdxYzFKTXd3bWxsV3QzQTZKQlJlaDhhaWhaNzY4NW1FelZwNm1FUzN6MXRqYm9SYkl4Zjlwa2lDOGY?oc=5","date":"2026-04-08","type":"deal","source":"The Globe and Mail","summary":"H.C. Wainwright Reaffirms Their Buy Rating on Silence Therapeutics (SLN) - The Globe and Mail","headline":"H.C. Wainwright Reaffirms Their Buy Rating on Silence Therapeutics (SLN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFBTR0JWM1E0X3VGQlNWYTRzU3FWNm96eVppU3drUHVhT09TRzlkVVFsSjVMTzN1VlUyalBxd3hTTE9EeFNHRm1iOVRobUU5VkV2NVZ0dXhIQXZPdm1leUltaUtjUy1KT1NubW1odw?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Silence Therapeutics Plc (SLN) - Stock Titan","headline":"If You Invested $1,000 in Silence Therapeutics Plc (SLN)","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-19","type":"pipeline","source":"simplywall.st","summary":"Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks - simplywall.st","headline":"Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-05","type":"earnings","source":"simplywall.st","summary":"Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive - simplywall.st","headline":"Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-31","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation - simplywall.st","headline":"Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation","sentiment":"neutral"},{"date":"2025-12-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQNnJsUkktYkd6ZWg3RjNGdDNGbmdqRmtMTWdYWDM3RkF3b1M4TTB2YlROT2NHemFvZ1JrTmczeUdRMVVmM2UwQ1ZJUUYxdXVIcjFqYjAtZG81TGRwbmQwLVVJODJ1dVhaWk8wYUlyMTV2T0hoSWhFXzNCaWYtcHZfQlZtZWhXZ1dFWnVjOTgxYmdGWFpwNEdfdzlZUWlYd2lLaXJNWnlXSVV0bFpESW5HUw?oc=5","date":"2025-12-09","type":"pipeline","source":"The Pharma Letter","summary":"Sanegene closes over $110 million series B to advance RNAi pipeline - The Pharma Letter","headline":"Sanegene closes over $110 million series B to advance RNAi pipeline","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-08-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOVEJRbFlxSjJaUEpjNmJ1VzR1cVhMNmpzSXRZVmdPSjd6Ylc0T3hvODg3WkNGMVdQa1pKUFRST0lDbTl6Z0lGbm1lWnhoMll2aGVyMHpXZjJQN2ZTLVZqS19fdkhuVGRxUDdaaU42dnFrUWlFUUZicWUtZE4xbEphVmdwQm85MDVCcnJ4dzdoWUppZldzNW8yODdXMDNPSXptWWNrUWg0QWNOVUhtbHZETVNkZjRyVWhDOGpRS0QtR3d3MDZXTTFlaVRybnphUXpUejNMa0UxS3Z3V2Nm?oc=5","date":"2025-05-06","type":"pipeline","source":"The Chronicle-Journal","summary":"Silence Therapeutics Welcomes Tim McInerney to Board of Directors - The Chronicle-Journal","headline":"Silence Therapeutics Welcomes Tim McInerney to Board of Directors - The Chronicle","sentiment":"neutral"}],"patents":[{"drugName":"STP-705","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Regeneron Pharmaceuticals","Alnylam Pharmaceuticals","Ionis Pharmaceuticals"],"therapeuticFocus":["RNAi Therapeutics","Cardiovascular Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":559000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":559000,"period":"2025-12-31"},{"value":43258000,"period":"2024-12-31"},{"value":43258000,"period":"2024-12-31"},{"value":31643000,"period":"2023-12-31"},{"value":31643000,"period":"2023-12-31"}],"grossProfit":344000,"grossProfitHistory":[{"period":"2025-12-31","value":344000},{"period":"2024-12-31","value":31448000},{"period":"2023-12-31","value":18776000},{"period":"2022-12-31","value":8192000}],"rdSpend":67753000,"rdSpendHistory":[{"period":"2025-12-31","value":67753000},{"period":"2024-12-31","value":67883000},{"period":"2023-12-31","value":56937000},{"period":"2022-12-31","value":43550000}],"sgaSpend":22344000,"operatingIncome":-89753000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-89753000},{"period":"2024-12-31","value":-63319000},{"period":"2023-12-31","value":-64383000},{"period":"2022-12-31","value":-61040000}],"netIncome":-88612000,"netIncomeHistory":[{"period":"2025-12-31","value":-88612000},{"period":"2024-12-31","value":-45309000},{"period":"2023-12-31","value":-54228000},{"period":"2022-12-31","value":-50334000}],"eps":-1.89,"epsHistory":[{"period":"2025-12-31","value":-1.89},{"period":"2024-12-31","value":-0.99},{"period":"2023-12-31","value":-1.47},{"period":"2022-12-31","value":-1.56}],"cash":11277000,"cashHistory":[{"period":"2025-12-31","value":11277000},{"period":"2024-12-31","value":121330000},{"period":"2023-12-31","value":68789000},{"period":"2022-12-31","value":66338299.185536}],"totalAssets":131442000,"totalLiabilities":69138000,"totalDebt":160000,"equity":62304000,"operatingCashflow":-62271000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-62271000},{"period":"2024-12-31","value":-67640000},{"period":"2023-12-31","value":-49462000},{"period":"2022-12-31","value":-57044000}],"capex":-55000,"capexHistory":[{"period":"2025-12-31","value":-55000},{"period":"2024-12-31","value":-211000},{"period":"2023-12-31","value":-56000},{"period":"2022-12-31","value":-545000}],"freeCashflow":-62326000,"dividendsPaid":null,"buybacks":null,"employees":88,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":3734000,"ebit":-12461000,"ebitda":-12348000,"period":"2025-12-31","revenue":34000,"epsBasic":null,"netIncome":-11770000,"rdExpense":8749000,"epsDiluted":null,"grossProfit":22000,"operatingIncome":-12461000},{"sga":5795000,"ebit":-26244000,"ebitda":-26088000,"period":"2025-09-30","revenue":159000,"epsBasic":-0.45,"netIncome":-20958000,"rdExpense":20544000,"epsDiluted":-0.45,"grossProfit":95000,"operatingIncome":-26244000},{"sga":5131000,"ebit":-22639000,"ebitda":-22491000,"period":"2025-06-30","revenue":224000,"epsBasic":-0.57,"netIncome":-27354000,"rdExpense":17647000,"epsDiluted":-0.57,"grossProfit":139000,"operatingIncome":-22639000},{"sga":7684000,"ebit":-28409000,"ebitda":-28271000,"period":"2025-03-31","revenue":142000,"epsBasic":-0.6,"netIncome":-28530000,"rdExpense":20813000,"epsDiluted":-0.6,"grossProfit":88000,"operatingIncome":-28409000},{"sga":5395113.78752,"ebit":-6663440.429831,"ebitda":-6544164.786489,"period":"2024-12-31","revenue":24327760.595233,"epsBasic":null,"netIncome":14174185.461747,"rdExpense":20404846.186787,"epsDiluted":null,"grossProfit":22721569.124948,"operatingIncome":-3078390.849358},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.75,"netIncome":null,"rdExpense":null,"epsDiluted":-0.75,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":7.01,"previousClose":6.98,"fiftyTwoWeekHigh":8.4,"fiftyTwoWeekLow":3.86,"fiftyTwoWeekRange":"3.86 - 8.4","fiftyDayAverage":6.58,"twoHundredDayAverage":5.96,"beta":0,"enterpriseValue":919150784,"forwardPE":-18,"priceToBook":5.32,"priceToSales":394.82,"enterpriseToRevenue":1095.53,"enterpriseToEbitda":-12.93,"pegRatio":0,"ebitda":-71083000,"ebitdaMargin":0,"freeCashflow":-44562752,"operatingCashflow":-65565000,"totalDebt":136000,"debtToEquity":0.3,"currentRatio":9.83,"returnOnAssets":-29.8,"returnOnEquity":-92.6,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":5,"targetMeanPrice":31.2,"targetHighPrice":75,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":24.4,"institutionHeldPercent":41.4,"sharesOutstanding":47234613,"floatShares":74748775,"sharesShort":2156496,"shortRatio":5.11,"shortPercentOfFloat":4.6,"epsTrailing":-1.62,"epsForward":-0.39,"revenuePerShare":0.02,"bookValue":1.32,"officers":[{"age":71,"name":"Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D","title":"Interim CEO & Chairman of the Board"},{"age":54,"name":"Ms. Rhonda L. Hellums","title":"Executive VP, CFO, Secretary & Executive Director"},{"age":66,"name":"Dr. Steven J. Romano M.D.","title":"Executive VP and Chief Research & Development Officer"},{"age":null,"name":"Dr. Marie Wikstrom Lindholm Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Ms. Gem Gokmen Hopkins","title":"Head of IR & Corporate Communications"},{"age":null,"name":"Mr. Jaimin B. Shah","title":"SVP & General Counsel"},{"age":null,"name":"Mr. J.P.  Gabriel","title":"Chief Technical Operations Officer"},{"age":null,"name":"Mr. Curtis  Rambaran M.D.","title":"Chief Medical Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.silence-therapeutics.com","phone":"44 20 3457 6900"}}